Navigation Links
Unigene Restates Policy on Analyst Reports
Date:3/13/2008

FAIRFIELD, New Jersey, March 13 /PRNewswire-FirstCall/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) announced that it did not issue, authorize or approve the press release titled "Stonegate Report About Unigene Laboratories Inc.", which was released yesterday. Pursuant to the Company's policies and procedures, Unigene does not endorse, confirm, validate or otherwise comment on reports issued by analysts and unrelated third parties. Any opinions, estimates or forecasts regarding Unigene's performance made by analysts or other third parties are theirs alone and do not represent the opinions, estimates, forecasts or predictions of Unigene or its management.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(r), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical(r) to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973)-882-0860 or visit http://www.unigene.com. For information about Fortical, visit http://www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.'s management's current expectations, estimates, beliefs, assumptions, and projections about Unigene's business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.

Contact:

Warren P. Levy

President and CEO

Unigene Laboratories, Inc.

110 Little Falls Road

Fairfield, NJ 07004

Tel.: +1-(973)-882-0860

Fax: +1-(973)-227-6088

E-Mail: wlevy@unigene.com


'/>"/>
SOURCE Unigene Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Stonegate Report About Unigene Laboratories Inc.
2. U.S. Preventive Medicine National Policy Advisor Gov. Tommy Thompson to Propose Prevention is the Solution at UBS Global Health Services Conference
3. DuPont Chief Science & Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum
4. Bioscience Group Warns Policymakers Against Complacency
5. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
6. Sales of Stem Cell Products Expected to Reach $87 Million in 2008, Leading Medical Industry Analyst Says
7. Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing
8. Medco to Webcast Annual Analyst Day Conference
9. Webcast Alert: Isis Pharmaceuticals Announces its Analyst & Investor Day
10. DURECT to Host Webcast in Conjunction with an Analysts Day on October 17
11. Nu Skin Enterprises to Hold 2007 Analyst Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... , ... August 14, 2017 , ... The Conference ... event, which will take place on September 6, 2017 at the Marriott Copley ... , Head of Experimental Medicine, Informatics, and Regulatory Strategy, Pfizer Innovative Research Lab, Pfizer, ...
(Date:8/11/2017)... WI (PRWEB) , ... August 11, 2017 , ... ... in food production, and, in particular, more natural alternatives to synthetic ingredients,” said ... innovation of Third Wave, with the established manufacturing presence and know-how of Biorigin ...
(Date:8/10/2017)... ... August 09, 2017 , ... Each year in the United States ... enough to live an independent lifestyle and, even worse, the one-year mortality rate is ... doctors at the University of California Davis Medical Center (Sacramento) and Second Xiangya Hospital ...
(Date:8/10/2017)... Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... optics and photonics, has announced an agreement establishing Kinokuniya Company Ltd. as its ... with SPIE as the exclusive sales representative for the SPIE Digital Library in ...
Breaking Biology Technology:
(Date:4/18/2017)... April 18, 2017  Socionext Inc., a global expert in SoC-based ... edge server, the M820, which features the company,s hybrid codec technology. ... by Tera Probe, Inc., will be showcased during the upcoming Medtec ... show at the Las Vegas Convention Center ... Click here ...
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
Breaking Biology News(10 mins):